Q-omics provides the consensus-scored NAT8L profile across patient tissues and cancer cell-line models. NAT8L expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, NAT8L is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, NAT8L RNA expression shows 16,065 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and KIRC as cancer lineages where NAT8L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NAT8L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NAT8L survival associations across molecular data types. NAT8L RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NAT8L RNA expression–survival associations across cancer types. High NAT8L expression shows unfavorable associations in ACC, UCEC, BLCA, UVM and MESO, but favorable associations in THCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for NAT8L RNA expression.
This table summarizes NAT8L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for NAT8L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NAT8L shows lower tumor expression in KIRC, KIRP and BRCA and higher tumor expression in THCA, LUAD and UCEC. The KIRC box plot shows higher NAT8L RNA expression in normal versus tumor tissue (log2 FC = −4.213, t-test p < 0.001).
This table shows molecular features associated with NAT8L in patient tissues and cancer cell lines. In patient samples, NAT8L shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, NAT8L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LUNG_SCLC.
